Sara Ali, MD
Internal Medicine · Hamilton, NJNPI 1467628255
Payments from drug & device makers
Across 165 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$388
- Novo Nordisk$318
- GSK$304
- Abbott$298
- AstraZeneca$288
- Boehringer Ingelheim$270
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,188100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 18 | $388 |
| Novo Nordisk | 22 | $318 |
| GSK | 15 | $304 |
| Abbott | 9 | $298 |
| AstraZeneca | 17 | $288 |
| Boehringer Ingelheim | 16 | $270 |
| Pfizer | 11 | $178 |
| Alkermes, Inc. | 4 | $178 |
| Amgen | 7 | $110 |
| Exact Sciences | 5 | $108 |
| Bayer | 5 | $95 |
| Sanofi-aventis U.S. LLC | 5 | $74 |
| Dexcom, Inc. | 4 | $73 |
| Genentech USA, Inc. | 3 | $64 |
| Medtronic | 1 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Eisai Inc. | 1 | $31 |
| Sumitomo Pharma America, Inc. | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 2 | $24 |
| Stryker | 1 | $23 |
| Astellas Pharma US Inc | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Biocomposites Inc | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Bausch Health US, LLC | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Merck | 1 | $11 |
| Impulse Dynamics (USA) Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$474
- AREXVY$125
- KISUNLA$122
- ARISTADA INITIO$118
- OCTRODE$109
How this compares
$3,188 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 77 | $99,042 |
| OzempicSemaglutide | 41 | $85,325 |
| EliquisApixaban | 72 | $84,380 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $66,623 |
| MounjaroTirzepatide | 47 | $61,962 |
| MyrbetriqMirabegron | 47 | $46,919 |
| ProliaDenosumab | 28 | $46,560 |
| JanuviaSitagliptin Phosphate | 54 | $45,625 |
| FarxigaDapagliflozin Propanediol | 40 | $43,637 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 37 | $42,819 |
| RybelsusSemaglutide | 28 | $40,626 |
| TrulicityDulaglutide | 26 | $34,204 |
| TradjentaLinagliptin | 29 | $30,696 |
| LinzessLinaclotide | 24 | $20,632 |
| XareltoRivaroxaban | 12 | $20,459 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Trijardy Xr, Synjardy Xr | $270 | $194,789160 claims |
| Novo NordiskOzempic, Rybelsus | $318 | $125,95169 claims |
| Lilly USA, LLCMounjaro, Trulicity | $388 | $96,16673 claims |
| PfizerEliquis | $178 | $84,38072 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $304 | $74,921101 claims |
| MerckJanuvia, Janumet Xr, Belsomra | $11 | $67,93187 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Nexium | $288 | $57,82271 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $46,91947 claims |
| AmgenProlia | $110 | $46,56028 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $74 | $42,81937 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $30 | $10,30912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Hamilton
- Samer HaddadHamilton$6.8M
- Sumitha ReddyHamilton$2M
- Matthew AdasofunjoHamilton$1.3M
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.